Telix Pharmaceuticals Files NDA for TLX250-CDx with FDA
Ticker: TLPPF · Form: 6-K · Filed: Aug 28, 2025 · CIK: 2007191
| Field | Detail |
|---|---|
| Company | Telix Pharmaceuticals Ltd (TLPPF) |
| Form Type | 6-K |
| Filed Date | Aug 28, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-update, NDA-filing, oncology, diagnostic
TL;DR
Telix Pharma just filed its NDA with the FDA for TLX250-CDx, a kidney cancer diagnostic. Big step!
AI Summary
On August 28, 2025, Telix Pharmaceuticals Limited announced a regulatory update regarding its TLX250-CDx product. The company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TLX250-CDx, a diagnostic agent for clear cell renal cell carcinoma (ccRCC). This submission is based on positive results from the Phase III Lumina-01 study.
Why It Matters
This FDA submission marks a significant step towards potential commercialization of TLX250-CDx, which could offer a new diagnostic tool for a common form of kidney cancer.
Risk Assessment
Risk Level: medium — Regulatory approvals are inherently uncertain, and the success of TLX250-CDx depends on FDA review and market adoption.
Key Players & Entities
- Telix Pharmaceuticals Limited (company) — Filer of the report
- TLX250-CDx (product) — Subject of the regulatory update
- U.S. Food and Drug Administration (FDA) (company) — Regulatory body receiving the application
- clear cell renal cell carcinoma (ccRCC) (medical_condition) — Indication for TLX250-CDx
- Lumina-01 (study) — Phase III study supporting the NDA
- August 28, 2025 (date) — Date of the announcement
FAQ
What is the specific indication for TLX250-CDx that Telix Pharmaceuticals is seeking FDA approval for?
Telix Pharmaceuticals is seeking FDA approval for TLX250-CDx as a diagnostic agent for clear cell renal cell carcinoma (ccRCC).
Which clinical trial data supported the New Drug Application (NDA) submission for TLX250-CDx?
The NDA submission for TLX250-CDx was supported by positive results from the Phase III Lumina-01 study.
On what date did Telix Pharmaceuticals announce the regulatory update regarding TLX250-CDx?
Telix Pharmaceuticals announced the regulatory update regarding TLX250-CDx on August 28, 2025.
To which regulatory body did Telix Pharmaceuticals submit the New Drug Application (NDA) for TLX250-CDx?
Telix Pharmaceuticals submitted the New Drug Application (NDA) for TLX250-CDx to the U.S. Food and Drug Administration (FDA).
What is the filing form associated with this announcement?
The filing form associated with this announcement is a Form 6-K.
Filing Stats: 281 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2025-08-28 16:09:57
Filing Documents
- zirc6kclr.htm (6-K) — 12KB
- zircprcrl.htm (EX-99.1) — 16KB
- recastpdf.htm (EX-99.2) — 1KB
- image1.gif (GRAPHIC) — 34KB
- recastpdf1.jpg (GRAPHIC) — 326KB
- recastpdf2.jpg (GRAPHIC) — 244KB
- recastpdf3.jpg (GRAPHIC) — 443KB
- recastpdf4.jpg (GRAPHIC) — 245KB
- recastpdf5.jpg (GRAPHIC) — 223KB
- recastpdf6.jpg (GRAPHIC) — 208KB
- recastpdf7.jpg (GRAPHIC) — 236KB
- recastpdf8.jpg (GRAPHIC) — 227KB
- recastpdf9.jpg (GRAPHIC) — 221KB
- recastpdf10.jpg (GRAPHIC) — 162KB
- 0002007191-25-000065.txt ( ) — 3567KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.           Telix Pharmaceuticals Limited       Date: August 28, 2025 By: /s/ Genevieve Ryan     Name: Genevieve Ryan     Title: Company Secretary